Assessment of What Patients and Healthcare Providers Value

Pancreatic Adenocarcinoma Clinical Trial

Official title:

"What Do You Value?" A Survey Study Assessing How Patients and Health Care Providers Weigh the Different Components of the Value Equation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04483349
• Other study ID #: 2020-0211
• Secondary ID: NCI-2020-0457720
• Status: Completed
• Start date: June 11, 2020
• Est. completion date: August 11, 2022

Study information

• Verified date: August 2022
• Source: M.D. Anderson Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To assess the importance patients place on each of the attributes of value (i.e., outcomes, quality of life [QOL], cost, experience), and how these patients’ views differ depending on the stage of their therapy (pretreatment, preoperative therapy, post-operative, long-term surveillance, recurrence).

Description:

PRIMARY OBJECTIVE: I. To assess the importance patients place on each of the attributes of value (i.e., outcomes, quality of life [QOL], cost, experience). SECONDARY OBJECTIVES: I. To assess which attributes of value (i.e., outcomes, QOL, cost, experience) health care providers (i.e., physicians, nurses, administrators) feel are most important in health care delivery. II. To assess how these patients' views differ depending on the stage of their therapy (pretreatment, preoperative therapy, post-operative, long-term surveillance, recurrence). III. To assess how patients' view differ to health providers. OUTLINE: Patients and healthcare providers complete a survey over 10-15 minutes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 397
• Est. completion date: August 11, 2022
• Est. primary completion date: August 11, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Any patient who has been treated, or is anticipated to be treated, for potentially resectable, biopsy-proven pancreatic adenocarcinoma, pancreatic neuroendocrine malignancy, or gastric adenocarcinoma
• Providers involved in the care of gastric and pancreatic cancer patients. Providers will include non-collaborative surgical oncologists, medical oncologists, radiation oncologists, administrators, nurses, mid-level providers
• Able to understand the description of the study and willing to participate

Exclusion Criteria:

• Inability to read and answer questions in English

Related Conditions & MeSH terms

• Adenocarcinoma
• Carcinoma, Islet Cell
• Carcinoma, Neuroendocrine
• Gastric Adenocarcinoma
• Pancreatic Adenocarcinoma
• Pancreatic Neuroendocrine Carcinoma

Intervention

Other:
• Survey Administration
Complete survey

Locations

Country	Name	City	State
United States	M D Anderson Cancer Center	Houston	Texas

Sponsors (2)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Importance patients place on each of the attributes of value (i.e., outcomes, quality of life [QOL], cost, experience)	We will calculate the mean rank of patients yielding usable data and its corresponding 95% confidence interval. Patient characteristics and survey items will be summarized using descriptive statistics, including means, standard deviations (SDs), proportions, range, and 95% confidence intervals (CIs), etc.	Survey completion up to 1 year
Secondary	Most important attributes of value to healthcare providers	Provider characteristics and survey items will be summarized using descriptive statistics, including means, SDs, proportions, range, and 95% CIs, etc.	Survey completion up to 1 year
Secondary	Importance care providers (i.e., physicians, nurses, administrators) place on each of the attributes of value (i.e., outcomes, quality of life [QOL], cost, experience)	Chi-square tests (or Fisher's exact test) will be used to compare the results between patients and providers.	Survey completion up to 1 year

External Links

•   Related Info